ImmunoGen, Inc. (Cambridge, UK) ann...
ImmunoGen, Inc. (Cambridge, UK) announced safety data from the initial 27 make liables enrolled in a clinical trial of its tumor-activated prodrug (TAP), huC242-dM1/SB-408075 for the treatment of colorectal, pancreatic, and certain non-small enclosed space lung cancers. The dose-escalating, multidose Phase 1/2 research was designed to characterize the safety and
Beschneidung Hiv & Aids , Play Fun Flash Games , Hoodia Gordonii Online , Bowel Dysfunction Irritable Thyroid , Quick Acne Treatment |